Temat: "INFLUENZA" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines.
Autorzy:: Lim CML; Infection and Immunity Research Strength, Jeffrey Cheah School of Medicine & Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia.
Komarasamy TV; Infection and Immunity Research Strength, Jeffrey Cheah School of Medicine & Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia.
Adnan NAAB; Infection and Immunity Research Strength, Jeffrey Cheah School of Medicine & Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia.
Radhakrishnan AK; Infection and Immunity Research Strength, Jeffrey Cheah School of Medicine & Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia.
Balasubramaniam VRMT; Infection and Immunity Research Strength, Jeffrey Cheah School of Medicine & Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia.; Pokaż więcej
Źródło:: Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2024 Mar; Vol. 18 (3), pp. e13276.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Influenza Vaccines*
Influenza, Human*/epidemiology
Influenza, Human*/prevention & control
Orthomyxoviridae*
Orthomyxoviridae Infections*
Humans ; Antibodies, Viral ; Hemagglutinins ; Viral Proteins ; Hemagglutinin Glycoproteins, Influenza Virus/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Antigenic drift and immunity gap explain reduction in protective responses against influenza A(H1N1)pdm09 and A(H3N2) viruses during the COVID-19 pandemic: a cross-sectional study of human sera collected in 2019, 2021, 2022, and 2023.
Autorzy:: Fossum E; Division of Infection Control, Department of Virology, Norwegian Institute of Public Health, PO Box 222 Skøyen, 0213, Oslo, Norway. .
Rohringer A; Division of Infection Control, Department of Virology, Norwegian Institute of Public Health, PO Box 222 Skøyen, 0213, Oslo, Norway.
Aune T; Division of Infection Control, Department of Virology, Norwegian Institute of Public Health, PO Box 222 Skøyen, 0213, Oslo, Norway.
Rydland KM; Division of Infection Control, Department of Vaccines, Norwegian Institute of Public Health, PO Box 222 Skøyen, 0213, Oslo, Norway.
Bragstad K; Division of Infection Control, Department of Virology, Norwegian Institute of Public Health, PO Box 222 Skøyen, 0213, Oslo, Norway.
Hungnes O; Division of Infection Control, Department of Virology, Norwegian Institute of Public Health, PO Box 222 Skøyen, 0213, Oslo, Norway.; Pokaż więcej
Źródło:: Virology journal [Virol J] 2024 Mar 06; Vol. 21 (1), pp. 57. Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*/epidemiology
Influenza, Human*/prevention & control
Influenza A Virus, H1N1 Subtype*
COVID-19*/epidemiology
Child ; Humans ; Cross-Sectional Studies ; Antigenic Drift and Shift ; Influenza A Virus, H3N2 Subtype ; Pandemics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Mosaic quadrivalent influenza vaccine single nanoparticle characterization.
Autorzy:: Yang RS; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Traver M; Twinbrook Imaging Facility, LIG, NIAID, NIH, Gaithersburg, MD, USA.
Barefoot N; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Stephens T; Vaccine Research Center Electron Microscopy Unit, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Alabanza C; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Manzella-Lapeira J; Twinbrook Imaging Facility, LIG, NIAID, NIH, Gaithersburg, MD, USA.
Zou G; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Wolff J; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Li Y; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Resto M; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Shadrick W; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Yang Y; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Ivleva VB; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Tsybovsky Y; Vaccine Research Center Electron Microscopy Unit, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Carlton K; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Brzostowski J; Twinbrook Imaging Facility, LIG, NIAID, NIH, Gaithersburg, MD, USA.
Gall JG; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Lei QP; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Feb 24; Vol. 14 (1), pp. 4534. Date of Electronic Publication: 2024 Feb 24.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza Vaccines*
Influenza, Human*/prevention & control
Nanoparticles*/chemistry
Humans ; Antibodies, Viral ; Hemagglutinin Glycoproteins, Influenza Virus ; Hemagglutinins ; Immunogenicity, Vaccine ; Clinical Trials as Topic

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.
Autorzy:: Rose AMC; Epiconcept, Paris, France.
Pozo F; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Martínez-Baz I; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Instituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain.
Mazagatos C; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Bossuyt N; Sciensano, Brussels, Belgium.
Cauchi JP; Department for Health Regulation, Health Promotion and Disease Prevention, Msida, Malta.
Petrović G; Croatian Institute of Public Health, Zagreb, Croatia.
Loghin II; St Parascheva Clinical Hospital of Infectious Diseases, Iasi, Romania.
Vaikutyte R; Lithuanian University of Health Sciences, Kaunas, Lithuania.
Buda S; Robert Koch Institute, Berlin, Germany.
Machado A; National Institute of Health Dr Ricardo Jorge, Lisbon, Portugal.
Duffy R; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
Oroszi B; Semmelweis University, Budapest, Hungary.
Howard J; Epiconcept, Paris, France.
Echeverria A; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Instituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain.
Andreu C; Subdirección de Epidemiología, Dirección General de Salud Pública, Servicio Extremeño de Salud, Mérida, Spain.
Barbezange C; Sciensano, Brussels, Belgium.
Džiugytė A; Department for Health Regulation, Health Promotion and Disease Prevention, Msida, Malta.
Nonković D; Teaching Public Health Institute of Split-Dalmatia County, Split, Croatia.
Popescu CP; Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania.
Majauskaite F; Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania.
Tolksdorf K; Robert Koch Institute, Berlin, Germany.
Gomez V; National Institute of Health Dr Ricardo Jorge, Lisbon, Portugal.
Domegan L; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
Horváth JK; Semmelweis University, Budapest, Hungary.
Castilla J; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Instituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain.
García M; Dirección General de Salud Pública, Departamento de Sanidad, Gobierno de Aragón, Zaragoza, Spain.
Demuyser T; Department of Microbiology and Infection control, UZ Brussel, Brussels, Belgium.
Borg ML; Department for Health Regulation, Health Promotion and Disease Prevention, Msida, Malta.
Tabain I; Croatian Institute of Public Health, Zagreb, Croatia.
Lazar M; 'Cantacuzino' National Military-Medical Institute for Research and Development, Bucharest, Romania.
Kubiliute I; Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania.
Dürrwald R; Robert Koch Institute, Berlin, Germany.
Guiomar R; National Institute of Health Dr Ricardo Jorge, Lisbon, Portugal.
O'Donnell J; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
Kristóf K; Semmelweis University, Budapest, Hungary.
Nicolay N; European Centre for Disease Prevention and Control, Stockholm, Sweden.
Bacci S; European Centre for Disease Prevention and Control, Stockholm, Sweden.
Kissling E; Epiconcept, Paris, France.; Pokaż więcej
Corporate Authors:: VEBIS SARI VE network team
Belgium SARI Surveillance Network (BelsariNet)
Źródło:: Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2024 Feb; Vol. 18 (2), pp. e13255.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*/epidemiology
Influenza, Human*/prevention & control
Influenza A Virus, H1N1 Subtype*/genetics
Influenza Vaccines*
Pneumonia*
Adult ; Humans ; Seasons ; Influenza A Virus, H3N2 Subtype/genetics ; Case-Control Studies ; Vaccine Efficacy ; Europe/epidemiology ; Hospitalization ; Hospitals ; Vaccination

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge.
Autorzy:: Reneer ZB; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, Unites States of America.
Bergeron HC; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, Unites States of America.
Reynolds S; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, Unites States of America.
Thornhill-Wadolowski E; Immorna Biotherapeutics, Morrisville, NC, United States of America.
Feng L; Immorna Biotherapeutics, Morrisville, NC, United States of America.
Bugno M; Immorna Biotherapeutics, Morrisville, NC, United States of America.
Truax AD; Immorna Biotherapeutics, Morrisville, NC, United States of America.
Tripp RA; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, Unites States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Apr 18; Vol. 19 (4), pp. e0297833. Date of Electronic Publication: 2024 Apr 18 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Influenza Vaccines*
Orthomyxoviridae Infections*
Influenza A virus*
Influenza, Human*/prevention & control
Animals ; Mice ; Humans ; Hemagglutinins ; mRNA Vaccines ; Antibodies, Viral ; Hemagglutinin Glycoproteins, Influenza Virus/genetics ; RNA, Messenger/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: An RNA-hydrolyzing recombinant minibody prevents both influenza A virus and coronavirus in co-infection models.
Autorzy:: Luong QXT; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
Hoang PT; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
Lee Y; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
Ayun RQ; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
Na K; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
Park S; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
Lin C; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
Ho PT; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
Lee TK; Ecological Risk Research Department, Korea Institute of Ocean Science & Technology, Geoje, 53201, Korea. .
Lee S; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Apr 11; Vol. 14 (1), pp. 8472. Date of Electronic Publication: 2024 Apr 11.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza A virus*
Influenza A Virus, H1N1 Subtype*
Coinfection*
Single-Chain Antibodies*/pharmacology
Single-Chain Antibodies*/metabolism
Coronavirus OC43, Human*
Humans ; RNA/metabolism ; Influenza A Virus, H3N2 Subtype

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Divergent Pathogenesis and Transmission of Highly Pathogenic Avian Influenza A(H5N1) in Swine.
Autorzy:: Arruda B
Baker ALV
Buckley A
Anderson TK
Torchetti M
Bergeson NH
Killian ML
Lantz K; Pokaż więcej
Źródło:: Emerging infectious diseases [Emerg Infect Dis] 2024 Apr; Vol. 30 (4), pp. 738-751. Date of Electronic Publication: 2024 Mar 13.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza A Virus, H5N1 Subtype*/genetics
Orthomyxoviridae Infections*
Animals ; Birds ; Influenza in Birds ; Mammals ; Phylogeny ; Poultry ; Swine

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Analysis of data from two influenza surveillance hospitals in Zhejiang province, China, for the period 2018-2022.
Autorzy:: Wang Y; Huzhou Center for Disease Control and Prevention, Huzhou, Zhejiang, China.
Liu Y; Huzhou Center for Disease Control and Prevention, Huzhou, Zhejiang, China.
Liu G; Huzhou Center for Disease Control and Prevention, Huzhou, Zhejiang, China.
Sun X; Huzhou Center for Disease Control and Prevention, Huzhou, Zhejiang, China.
Zhang Z; Huzhou Center for Disease Control and Prevention, Huzhou, Zhejiang, China.
Shen J; Huzhou Center for Disease Control and Prevention, Huzhou, Zhejiang, China.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Feb 28; Vol. 19 (2), pp. e0299488. Date of Electronic Publication: 2024 Feb 28 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*/prevention & control
Influenza A Virus, H1N1 Subtype*
COVID-19*/epidemiology
Nucleic Acids*
Child ; Humans ; Influenza A Virus, H3N2 Subtype ; Pandemics ; China/epidemiology ; Seasons ; Hospitals ; Sentinel Surveillance

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: A pan-influenza monoclonal antibody neutralizes H5 strains and prophylactically protects through intranasal administration.
Autorzy:: Beukenhorst AL; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. .; Leyden Laboratories BV, Leiden, The Netherlands. .; Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. .
Frallicciardi J; Leyden Laboratories BV, Leiden, The Netherlands.
Rice KL; Leyden Laboratories BV, Leiden, The Netherlands.
Koldijk MH; Leyden Laboratories BV, Leiden, The Netherlands.
Moreira de Mello JC; Leyden Laboratories BV, Leiden, The Netherlands.
Klap JM; Leyden Laboratories BV, Leiden, The Netherlands.
Hadjichrysanthou C; Department of Mathematics, University of Sussex, Brighton, UK.
Koch CM; Leyden Laboratories BV, Leiden, The Netherlands.
da Costa KAS; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and University of Greenwich, Chatham, UK.
Temperton N; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and University of Greenwich, Chatham, UK.
de Jong BA; Leyden Laboratories BV, Leiden, The Netherlands.
Vietsch H; Leyden Laboratories BV, Leiden, The Netherlands.
Ziere B; Leyden Laboratories BV, Leiden, The Netherlands.
Julg B; Leyden Laboratories BV, Leiden, The Netherlands.
Koudstaal W; Leyden Laboratories BV, Leiden, The Netherlands.
Goudsmit J; Leyden Laboratories BV, Leiden, The Netherlands.; Departments of Epidemiology, Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Feb 15; Vol. 14 (1), pp. 3818. Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*
Influenza Vaccines*
Influenza A Virus, H5N1 Subtype*
Humans ; Animals ; Mice ; Antibodies, Monoclonal ; Antibodies, Neutralizing ; Administration, Intranasal ; Antibodies, Viral ; Epitopes ; Hemagglutinin Glycoproteins, Influenza Virus ; Mice, Inbred BALB C

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: P80 natural essence spray and lozenges provide respiratory protection against Influenza A, B, and SARS-CoV-2.
Autorzy:: Zaderer V; Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstraße 41, Innsbruck, 6020, Austria.
Diem G; Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstraße 41, Innsbruck, 6020, Austria.
Posch W; Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstraße 41, Innsbruck, 6020, Austria.
Jakschitz T; ADSI - Austrian Drug Screening Institute GmbH, Innrain 66, Innsbruck, 6020, Austria.
Bonn GK; ADSI - Austrian Drug Screening Institute GmbH, Innrain 66, Innsbruck, 6020, Austria.
Bellmann-Weiler R; Department of Internal Medicine II, Medical University of Innsbruck, Anichstraße 35, Innsbruck, Austria.
Huber LA; ADSI - Austrian Drug Screening Institute GmbH, Innrain 66, Innsbruck, 6020, Austria. .; Institute of Cell Biology, Biocenter, Medical University of Innsbruck, Innrain 81/82, Innsbruck, 6020, Austria. .
Wilflingseder D; Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstraße 41, Innsbruck, 6020, Austria. .; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2024 Feb 28; Vol. 25 (1), pp. 102. Date of Electronic Publication: 2024 Feb 28.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*/prevention & control
COVID-19*
Humans ; Influenza A Virus, H3N2 Subtype ; SARS-CoV-2 ; Inflammation
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Scalable gradients enable Hamiltonian Monte Carlo sampling for phylodynamic inference under episodic birth-death-sampling models.
Autorzy:: Shao Y; Department of Biostatistics, University of California, Los Angeles, California, United States of America.
Magee AF; Department of Biomathematics, University of California, Los Angeles, California, United States of America.
Vasylyeva TI; Department of Medicine, University of California San Diego, La Jolla, California, United States of America.; Department of Population Health and Disease Prevention, University of California Irvine, Irvine, California, United States of America.
Suchard MA; Department of Biostatistics, University of California, Los Angeles, California, United States of America.; Department of Biomathematics, University of California, Los Angeles, California, United States of America.; Department of Human Genetics, Universtiy of California, Los Angeles, California, United States of America.; Pokaż więcej
Źródło:: PLoS computational biology [PLoS Comput Biol] 2024 Mar 29; Vol. 20 (3), pp. e1011640. Date of Electronic Publication: 2024 Mar 29 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*/epidemiology
Epidemics*
Hemorrhagic Fever, Ebola*/epidemiology
Humans ; Influenza A Virus, H3N2 Subtype ; Algorithms ; Monte Carlo Method

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Persistent predominance of the Victoria lineage of influenza B virus during COVID-19 epidemic in Nanchang, China.
Autorzy:: Zhou X; Jiangxi University of Chinese Medicine Nanchang China.; Nanchang Center for Disease Control and Prevention Nanchang China.
Lin Z; Jiangxi University of Chinese Medicine Nanchang China.
Tu J; Nanchang Center for Disease Control and Prevention Nanchang China.
Zhu C; Third Hospital of Nanchang Nanchang China.
Li H; Nanchang Center for Disease Control and Prevention Nanchang China.; Pokaż więcej
Źródło:: Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2023 Dec 10; Vol. 17 (12), pp. e13226. Date of Electronic Publication: 2023 Dec 10 (Print Publication: 2023).
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*/epidemiology
Influenza A Virus, H1N1 Subtype*
COVID-19*/epidemiology
Humans ; Influenza B virus/genetics ; Influenza A Virus, H3N2 Subtype ; Pandemics ; China/epidemiology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Genome characterization of influenza A and B viruses in New South Wales, Australia, in 2019: A retrospective study using high-throughput whole genome sequencing.
Autorzy:: Wang X; School of Biomedical Sciences, Faculty of Medicine and Health University of New South Wales Sydney New South Wales Australia.; Virology Research Laboratory, Serology and Virology Division (SAViD), NSW Health Pathology Prince of Wales Hospital Sydney New South Wales Australia.
Kim KW; Virology Research Laboratory, Serology and Virology Division (SAViD), NSW Health Pathology Prince of Wales Hospital Sydney New South Wales Australia.; Discipline of Paediatrics and Child Health, School of Clinical Medicine, Faculty of Medicine and Health University of New South Wales Sydney New South Wales Australia.
Walker G; School of Biomedical Sciences, Faculty of Medicine and Health University of New South Wales Sydney New South Wales Australia.; Virology Research Laboratory, Serology and Virology Division (SAViD), NSW Health Pathology Prince of Wales Hospital Sydney New South Wales Australia.
Stelzer-Braid S; School of Biomedical Sciences, Faculty of Medicine and Health University of New South Wales Sydney New South Wales Australia.; Virology Research Laboratory, Serology and Virology Division (SAViD), NSW Health Pathology Prince of Wales Hospital Sydney New South Wales Australia.
Scotch M; Biodesign Center for Environmental Health Engineering, Biodesign Institute Arizona State University Phoenix Arizona USA.; College of Health Solutions Arizona State University Phoenix Arizona USA.; Kirby Institute University of New South Wales Sydney New South Wales Australia.
Rawlinson WD; School of Biomedical Sciences, Faculty of Medicine and Health University of New South Wales Sydney New South Wales Australia.; Virology Research Laboratory, Serology and Virology Division (SAViD), NSW Health Pathology Prince of Wales Hospital Sydney New South Wales Australia.; Pokaż więcej
Źródło:: Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2024 Jan; Vol. 18 (1), pp. e13252.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*
Herpesvirus 1, Cercopithecine*/genetics
Influenza Vaccines*
Humans ; Retrospective Studies ; Influenza A Virus, H3N2 Subtype/genetics ; New South Wales/epidemiology ; Phylogeny ; Hemagglutinin Glycoproteins, Influenza Virus/genetics ; Australia ; Seasons ; Whole Genome Sequencing

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Amphiphilic Sialic Acid Derivatives as Potential Dual-Specific Inhibitors of Influenza Hemagglutinin and Neuraminidase.
Autorzy:: Lőrincz EB; Department of Pharmaceutical Chemistry, University of Debrecen, H-4032 Debrecen, Hungary.; Doctoral School of Pharmaceutical Sciences, University of Debrecen, H-4032 Debrecen, Hungary.
Herczeg M; Department of Pharmaceutical Chemistry, University of Debrecen, H-4032 Debrecen, Hungary.
Houser J; National Centre for Biomolecular Research, Masaryk University, 611 37 Brno, Czech Republic.; Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic.
Rievajová M; Department of Biochemistry, Faculty of Science, Masaryk University, 611 37 Brno, Czech Republic.
Kuki Á; Department of Applied Chemistry, University of Debrecen, H-4032 Debrecen, Hungary.
Malinovská L; National Centre for Biomolecular Research, Masaryk University, 611 37 Brno, Czech Republic.; Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic.
Naesens L; Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium.
Wimmerová M; National Centre for Biomolecular Research, Masaryk University, 611 37 Brno, Czech Republic.; Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic.; Department of Biochemistry, Faculty of Science, Masaryk University, 611 37 Brno, Czech Republic.
Borbás A; Department of Pharmaceutical Chemistry, University of Debrecen, H-4032 Debrecen, Hungary.; National Laboratory of Virology, University of Pécs, H-7624 Pécs, Hungary.; HUN-REN-UD Molecular Recognition and Interaction Research Group, University of Debrecen, H-4032 Debrecen, Hungary.
Herczegh P; Department of Pharmaceutical Chemistry, University of Debrecen, H-4032 Debrecen, Hungary.
Bereczki I; Department of Pharmaceutical Chemistry, University of Debrecen, H-4032 Debrecen, Hungary.; National Laboratory of Virology, University of Pécs, H-7624 Pécs, Hungary.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Dec 08; Vol. 24 (24). Date of Electronic Publication: 2023 Dec 08.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*/drug therapy
Influenza A Virus, H1N1 Subtype*
Humans ; N-Acetylneuraminic Acid/pharmacology ; N-Acetylneuraminic Acid/metabolism ; Hemagglutinins/pharmacology ; Neuraminidase/metabolism ; Influenza A Virus, H3N2 Subtype ; Neuraminic Acids ; Hemagglutinin Glycoproteins, Influenza Virus/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study.
Autorzy:: Maurel M; Epiconcept Paris France.
Pozo F; National Centre for Microbiology Institute of Health Carlos III Madrid Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) Madrid Spain.
Pérez-Gimeno G; National Centre for Microbiology Institute of Health Carlos III Madrid Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) Madrid Spain.
Buda S; Department for Infectious Disease Epidemiology, Respiratory Infections Unit Robert Koch Institute Berlin Germany.
Sève N; Sorbonne Université INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136) Paris France.
Oroszi B; National Laboratory for Health Security, Epidemiology and Surveillance Centre Semmelweis University Budapest Hungary.
Hooiveld M; Nivel Utrecht the Netherlands.
Gomez V; Instituto Nacional de Saúde Dr. Ricardo Jorge Lisbon Portugal.
Domegan L; HSE-Health Protection Surveillance Centre Dublin Ireland.
Martínez-Baz I; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) Madrid Spain.; Instituto de Salud Pública de Navarra (IdiSNA) Pamplona Spain.
Ilić M; Croatian Institute of Public Health Zagreb Croatia.
Carnahan AS; The Public Health Agency of Sweden (PHAS) Stockholm Sweden.
Mihai ME; 'Cantacuzino' National Military Medical Institute for Research and Development Bucharest Romania.
Martínez A; Subdirección General de Vigilancia y Respuesta a Emergencias de Salud Pública, Agencia de Salud Pública de Catalunya Barcelona Spain.
Goerlitz L; Department for Infectious Disease Epidemiology, Respiratory Infections Unit Robert Koch Institute Berlin Germany.
Enouf V; Centre National de Référence Virus des Infections Respiratoire (CNR VIR), Institut Pasteur Paris France.
Horváth JK; National Laboratory for Health Security, Epidemiology and Surveillance Centre Semmelweis University Budapest Hungary.
Dijkstra F; National Institute for Public Health and the Environment (RIVM) Bilthoven the Netherlands.
Rodrigues AP; Instituto Nacional de Saúde Dr. Ricardo Jorge Lisbon Portugal.
Bennett C; National Virus Reference Laboratory University College Dublin Dublin Ireland.
Trobajo-Sanmartín C; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) Madrid Spain.; Instituto de Salud Pública de Navarra (IdiSNA) Pamplona Spain.
Mlinarić I; Croatian Institute of Public Health Zagreb Croatia.
Latorre-Margalef N; The Public Health Agency of Sweden (PHAS) Stockholm Sweden.
Ivanciuc A; 'Cantacuzino' National Military Medical Institute for Research and Development Bucharest Romania.
Lopez A; Subdirección General de Epidemiologia y Vigilancia de la Salud Valencia Spain.
Dürrwald R; National Reference Centre for Influenza Robert Koch Institute Berlin Germany.
Falchi A; Laboratoire de Virologie Université de Corse-Inserm Corte France.
Túri G; National Laboratory for Health Security, Epidemiology and Surveillance Centre Semmelweis University Budapest Hungary.
Meijer A; National Institute for Public Health and the Environment (RIVM) Bilthoven the Netherlands.
Melo A; Instituto Nacional de Saúde Dr. Ricardo Jorge Lisbon Portugal.
O'Donnell J; HSE-Health Protection Surveillance Centre Dublin Ireland.
Castilla J; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) Madrid Spain.; Instituto de Salud Pública de Navarra (IdiSNA) Pamplona Spain.
Vučina VV; Croatian Institute of Public Health Zagreb Croatia.
Hagey TS; The Public Health Agency of Sweden (PHAS) Stockholm Sweden.
Lazar M; 'Cantacuzino' National Military Medical Institute for Research and Development Bucharest Romania.
Kaczmarek M; European Centre for Disease Prevention and Control Stockholm Sweden.
Bacci S; European Centre for Disease Prevention and Control Stockholm Sweden.
Kissling E; Epiconcept Paris France.; Pokaż więcej
Corporate Authors:: VEBIS study team
Źródło:: Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2024 Jan 10; Vol. 18 (1), pp. e13243. Date of Electronic Publication: 2024 Jan 10 (Print Publication: 2024).
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: Influenza A virus*
Influenza A Virus, H1N1 Subtype*/genetics
Influenza Vaccines*
Influenza, Human*/epidemiology
Influenza, Human*/prevention & control
Child ; Humans ; Europe/epidemiology ; Influenza A Virus, H3N2 Subtype/genetics ; Primary Health Care ; Vaccine Efficacy ; Infant, Newborn ; Infant ; Child, Preschool ; Adolescent ; Young Adult ; Adult ; Middle Aged

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: A new class of antibodies that overcomes a steric barrier to cross-group neutralization of influenza viruses.
Autorzy:: Simmons HC; Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
Watanabe A; Department of Integrative Immunobiology, Duke University, Durham, North Carolina, United States of America.
Oguin Iii TH; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Van Itallie ES; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Wiehe KJ; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Sempowski GD; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Kuraoka M; Department of Integrative Immunobiology, Duke University, Durham, North Carolina, United States of America.
Kelsoe G; Department of Integrative Immunobiology, Duke University, Durham, North Carolina, United States of America.; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
McCarthy KR; Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.; Pokaż więcej
Źródło:: PLoS biology [PLoS Biol] 2023 Dec 21; Vol. 21 (12), pp. e3002415. Date of Electronic Publication: 2023 Dec 21 (Print Publication: 2023).
Typ publikacji:: Journal Article
MeSH Terms:: Influenza Vaccines*
Influenza, Human*
Humans ; Antibodies, Viral ; Hemagglutinin Glycoproteins, Influenza Virus/chemistry ; Influenza A Virus, H3N2 Subtype ; Binding Sites

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Genomic Analysis of Influenza A and B Viruses Carrying Baloxavir Resistance-Associated Substitutions Serially Passaged in Human Epithelial Cells.
Autorzy:: Hickerson BT; Division of Biotechnology Review and Research II, Food and Drug Administration, Silver Spring, MD 20993, USA.
Huang BK; Division of Biotechnology Review and Research II, Food and Drug Administration, Silver Spring, MD 20993, USA.
Petrovskaya SN; Division of Biotechnology Review and Research III, Food and Drug Administration, Silver Spring, MD 20993, USA.
Ilyushina NA; Division of Biotechnology Review and Research II, Food and Drug Administration, Silver Spring, MD 20993, USA.; Pokaż więcej
Źródło:: Viruses [Viruses] 2023 Dec 16; Vol. 15 (12). Date of Electronic Publication: 2023 Dec 16.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*
Herpesvirus 1, Cercopithecine*
Influenza A Virus, H1N1 Subtype*/genetics
Influenza A Virus, H1N1 Subtype*/metabolism
Thiepins*/pharmacology
Humans ; Oxazines/pharmacology ; Pyridines/pharmacology ; Influenza A Virus, H3N2 Subtype/genetics ; Influenza A Virus, H3N2 Subtype/metabolism ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Epithelial Cells/metabolism ; Genomics ; Viral Proteins/genetics ; Nucleotidyltransferases

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity.
Autorzy:: Nittayananta W; Faculty of Dentistry, Thammasat University, Pathum Thani, Thailand. .
Lerdsamran H; Center for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Chutiwitoonchai N; National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, Thailand.
Promsong A; Faculty of Medicine, Princess of Naradhiwas University, Narathiwat, Thailand.
Srichana T; Drug Delivery System Excellence Center, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, Thailand.; Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Netsomboon K; Faculty of Pharmacy, Thammasat University, Pathum Thani, Thailand.
Prasertsopon J; Center for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Kerdto J; Thammasat Hospital, Thammasat University, Pathum Thani, Thailand.; Pokaż więcej
Źródło:: Virology journal [Virol J] 2024 Jan 23; Vol. 21 (1), pp. 26. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*
Curcumin*
Influenza A Virus, H1N1 Subtype*
COVID-19*
Orthomyxoviridae Infections*
Animals ; Dogs ; Humans ; SARS-CoV-2 ; Immunity, Mucosal ; Influenza A Virus, H3N2 Subtype ; Madin Darby Canine Kidney Cells ; Antiviral Agents

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: The Chinese Hamster Ovary Cell-Based H9 HA Subunit Avian Influenza Vaccine Provides Complete Protection against the H9N2 Virus Challenge in Chickens.
Autorzy:: Zhu S; Department of Biopharmacy, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Nie Z; Department of Biopharmacy, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Che Y; Zhejiang Novo Biotech Co., Ltd., Shaoxing 312366, China.
Shu J; Department of Biopharmacy, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Wu S; Zhejiang Novo Biotech Co., Ltd., Shaoxing 312366, China.
He Y; Department of Biopharmacy, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Wu Y; Zhejiang Novo Biotech Co., Ltd., Shaoxing 312366, China.
Qian H; Zhejiang Novo Biotech Co., Ltd., Shaoxing 312366, China.
Feng H; Department of Biopharmacy, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Zhang Q; Zhejiang Novo Biotech Co., Ltd., Shaoxing 312366, China.; Pokaż więcej
Źródło:: Viruses [Viruses] 2024 Jan 22; Vol. 16 (1). Date of Electronic Publication: 2024 Jan 22.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza in Birds*
Influenza A Virus, H9N2 Subtype*/genetics
Influenza Vaccines*
Animals ; Humans ; Cricetinae ; Chickens ; Hemagglutinins ; Cricetulus ; CHO Cells ; Antibodies, Viral ; Vaccines, Subunit ; Hemagglutinin Glycoproteins, Influenza Virus/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Genomic Analyses Uncover Evolutionary Features of Influenza A/H3N2 Viruses in Yunnan Province, China, from 2017 to 2022.
Autorzy:: Zhang M; Department of Acute Infectious Diseases Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming 650022, China.
Zhou J; Department of Acute Infectious Diseases Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming 650022, China.
Ni R; Department of Acute Infectious Diseases Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming 650022, China.
Zhao X; Department of Acute Infectious Diseases Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming 650022, China.
Chen Y; Department of Acute Infectious Diseases Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming 650022, China.
Sun Y; Department of Acute Infectious Diseases Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming 650022, China.
Liu Z; Department of Acute Infectious Diseases Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming 650022, China.
Han X; Department of Acute Infectious Diseases Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming 650022, China.
Luo C; Department of Acute Infectious Diseases Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming 650022, China.
Fu X; Department of Acute Infectious Diseases Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming 650022, China.
Shao Y; State Key Laboratory of Genetic Resources and Evolution, Chinese Academy of Sciences, Kunming Institute of Zoology, Kunming 650201, China.; Pokaż więcej
Źródło:: Viruses [Viruses] 2024 Jan 18; Vol. 16 (1). Date of Electronic Publication: 2024 Jan 18.
Typ publikacji:: Journal Article
MeSH Terms:: Influenza, Human*/epidemiology
Influenza A virus*
Humans ; Influenza A Virus, H3N2 Subtype/genetics ; China/epidemiology ; Genomics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""INFLUENZA"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji